Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

<p>Abstract</p> <p>Background</p> <p>Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because they release large amounts of various mediators...

Full description

Bibliographic Details
Main Authors:	Vermersch Patrick, Benrabah Rabah, Schmidt Nicolas, Zéphir Hélène, Clavelou Pierre, Vongsouthi Cyrille, Dubreuil Patrice, Moussy Alain, Hermine Olivier
Format:	Article
Language:	English
Published:	BMC 2012-06-01
Series:	BMC Neurology
Subjects:	Multiple sclerosis Primary progressive multiple sclerosis Secondary progressive multiple sclerosis Tyrosine kinase inhibitor Masitinib Mast cells
Online Access:	http://www.biomedcentral.com/1471-2377/12/36

Similar Items

Deciphering Multiple Sclerosis Progression
by: Virginia Meca-Lallana, et al.
Published: (2021-04-01)

Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial
by: Ethel Ciampi, et al.
Published: (2020-05-01)

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-11-01)

Stem Cells Therapy in Multiple Sclerosis - A New Hope for Progressive Forms
by: Ayache SS, et al.
Published: (2016-05-01)

Malignant multiple sclerosis: clinical and demographic prognostic factors
by: Fabrício Hampshire-Araújo, et al.

Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis
by: Katharina Breitkopf, et al.
Published: (2020-08-01)

The Factors Associated With Olfactory Dysfunction in Patients with Multiple Sclerosis
by: Mostafa Almasi, et al.
Published: (2021-01-01)

Mitoxantrone in the treatment of multiple sclerosis: a single-center experience
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-06-01)

New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
by: D. S. Kasatkin, et al.
Published: (2021-02-01)

OCRELIZUMAB IN THE TREATMENT OF PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS
by: E. V. Popova
Published: (2018-02-01)

Clinical characteristics of multiple sclerosis in the Tomsk region
by: V M Alifirova, et al.
Published: (2012-06-01)

New possibilities for the therapy of secondary progressive multiple sclerosis
by: A. M. Petrov, et al.
Published: (2019-12-01)

Arm Ergometry to Improve Mobility in Progressive Multiple Sclerosis (AMBOS)—Results of a Pilot Randomized Controlled Trial
by: Inga Heinrich, et al.
Published: (2021-07-01)

The Importance of Cerebellar Involvement in Identifying the Prognosis in Patients with Progressive Multiple Sclerosis
by: Egemen İdiman, et al.
Published: (2004-04-01)

Linear Modeling of Multiple Sclerosis and Its Subgroubs
by: Yeliz Karaca, et al.
Published: (2015-03-01)

The Role of B Cells in Primary Progressive Multiple Sclerosis
by: Jameson P. Holloman, et al.
Published: (2021-06-01)

Findings of Optical Coherence Tomography of Retinal Nerve Fiber Layer in Two Common Types of Multiple Sclerosis
by: Gholamali Yousefipour, et al.
Published: (2016-06-01)

Should We Use Clinical Tools to Identify Disease Progression?
by: Hernan Inojosa, et al.
Published: (2021-01-01)

Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects»
by: N. V. Khachanova, et al.
Published: (2019-12-01)

Construction of a User-Led Resource for People Transitioning to Secondary Progressive Multiple Sclerosis: Results of an International Nominal Group Study
by: Ambra Mara Giovannetti, et al.
Published: (2020-08-01)

Mitochondrial Dysfunction in Multiple Sclerosis: A Systematic Review
by: Alia Saberi, et al.
Published: (2019-02-01)

Late onset multiple sclerosis: concerns in aging patients
by: Claudia Beatriz de Campos Lotti, et al.

Effect of disease duration on personality type in multiple sclerosis patients and healthy individual
by: Sahar Vesal, et al.
Published: (2016-01-01)

CUTANEOUS MELANOMA IN A PATIENT WITH MULTIPLE SCLEROSIS: CASE REPORT AND REVIEW OF LITERATURE
by: Zoran Ćeranić, et al.
Published: (2012-01-01)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
by: Gajofatto A
Published: (2017-11-01)

Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland
by: Katarzyna Kapica-Topczewska, et al.
Published: (2021-02-01)

Comparing power and activity of lower body muscles in two types of multiple sclerosis patients and healthy individuals
by: Talebi V, et al.
Published: (2020-05-01)

Serum Anti-oligodendrocyte Autoantibodies in Patients With Multiple Sclerosis Detected by a Tissue-Based Immunofluorescence Assay
by: Yukino Miyachi, et al.
Published: (2021-08-01)

Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis
by: Petros Pousinis, et al.
Published: (2020-09-01)

Monoclonal antibodies in the treatment of multiple sclerosis: from clinical research to practical application
by: N. Yu. Lashch
Published: (2020-07-01)

Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
by: Jorge Correale, et al.
Published: (2019-02-01)

Cortical Demyelination in Multiple Sclerosis
by: J Gordon Millichap
Published: (2008-02-01)

Natural course of multiple sclerosis in the first five years of the disease in the Kujawsko-Pomorskie district
by: Łukasz Rzepiński, et al.
Published: (2016-03-01)

Development of a sensitive outcome for economical drug screening for progressive multiple sclerosis treatment
by: Peter Kosa, et al.
Published: (2016-08-01)

Optical Coherence Tomography and Visual Evoked Potentials as Prognostic and Monitoring Tools in Progressive Multiple Sclerosis
by: Simone Guerrieri, et al.
Published: (2021-08-01)

Machine Learning Use for Prognostic Purposes in Multiple Sclerosis
by: Ruggiero Seccia, et al.
Published: (2021-02-01)

Disability and progression in Afro-descendant patients with multiple sclerosis
by: Juliana Calvet Kallenbach Aurenção, et al.

Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review
by: Elsbernd PM, et al.
Published: (2021-06-01)

Association of body mass index with progression and prediction of multiple sclerosis
by: Tadić Daliborka, et al.
Published: (2020-01-01)

The experience of using ocrelizumab in routine practice
by: E. V. Popova, et al.
Published: (2020-03-01)